Should I Buy CEVA? CEVA 2026 Analysis

Should You Buy CEVA Inc (CEVA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

22.170

1 Day change

-1.51%

52 Week Range

38.940

Analysis Updated At

2026/01/28

Buy (long-term). At ~$22.62, CEVA offers an attractive risk/reward for a beginner long-term investor who wants to enter now (not wait for an ideal technical setup). Wall Street is upgrading and raising targets to $35, the latest quarter shows improving growth and narrowing losses with very high gross margins, and options positioning shows strong call open interest (bullish longer-dated positioning) alongside short-term put-heavy volume (near-term hedging). Given no proprietary “must-buy-today” signals and a bearish moving-average stack, this is best approached as a buy-now with room for volatility into the 2026-02-17 earnings catalyst.

Technical Analysis

Trend/Price action: The trend is currently bearish-to-neutral. - Moving averages: Bearish alignment (SMA_200 > SMA_20 > SMA_5), which typically signals the stock is trading below longer-term trend and rallies can face overhead supply. - MACD: Histogram is negative (-0.0377) and negatively expanding, suggesting downside momentum has not fully exhausted. - RSI(6): 48.16 (neutral), consistent with consolidation rather than an oversold bounce. Key levels: - Pivot: 22.948 (price below pivot is slightly bearish near-term) - Support: S1 22.085 then S2 21.552 - Resistance: R1 23.811 then R2 24.344 Practical read: Buying here is buying into a weak technical structure, but close support is nearby (~22.09), and a reclaim of ~22.95–23.81 would improve momentum. Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Sentiment read: - Open Interest Put-Call Ratio (0.11): Very call-heavy positioning overall, typically a bullish signal for broader expectations. - Option Volume Put-Call Ratio (2.24): Put volume is dominating today, which often indicates near-term caution/hedging despite bullish longer-term positioning. Activity/interest: - Today’s options volume: 460 vs much lower recent averages (volume spike vs 30-day avg shown as ~766%); elevated activity can precede larger price moves. - Notable flow mentioned in news: $30 strike calls saw meaningful interest, suggesting upside speculation. Volatility: - Implied vol (30D) ~68% vs historical vol ~83%: options price in high volatility, but not exceeding recent realized volatility; expect larger-than-average swings.

Technical Summary

Sell

Buy

Positive Catalysts

1) Analyst upgrades/target raises: Barclays and Roth both raised price targets to $35 and reiterated bullish ratings (Overweight/Buy), citing strong licensing and end-market royalty growth and AI IP (NeuPro) momentum.
2) Improving fundamentals: Q3 showed revenue growth and materially improved profitability metrics (loss narrowing), supporting a longer-term re-rating if momentum continues.
3) Event catalyst: Next earnings (QDEC 2025) on 2026-02-17 pre-market—potential upside catalyst if licensing/royalties and AI IP contribution remain strong.
4) Options positioning: Extremely low put/call open interest ratio suggests market is positioned for upside over time.

Neutral/Negative Catalysts

1) Technical trend is not supportive: bearish moving-average stack and weakening MACD imply the stock can drift lower before a sustained uptrend develops.
2) Short-term caution from options volume: put-heavy volume (put/call volume ratio 2.24) suggests traders are hedging or expecting near-term weakness.
3) High volatility environment: elevated IV/HV increases the chance of sharp drawdowns even if the long-term thesis is intact.
4) No supportive positioning signals from flows: hedge funds and insiders are reported as neutral (no strong accumulation signal).

Financial Performance

Latest quarter: 2025/Q3. - Revenue: $28.384M, +4.33% YoY (moderate growth). - Net income: -$2.509M, improved +91.38% YoY (loss narrowing significantly). - EPS: -$0.10, improved +66.67% YoY. - Gross margin: 87.52%, +3.10% YoY (very strong margin profile; supports operating leverage if revenue accelerates). Overall: growth is positive but not explosive; the key positive is improving profitability and exceptionally high gross margin, consistent with an IP/licensing model.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: analysts are becoming more constructive. - 2025-11-10: Roth Capital raised PT to $35 from $30; reiterated Buy. Rationale: Q3 beat, broad end-market royalty growth, robust licensing, and rising NeuPro AI IP contribution. - 2025-11-11: Barclays raised PT to $35 from $30; reiterated Overweight. Wall Street pros: improving royalty/licensing trends, AI IP tailwinds, and better profitability trajectory. Wall Street cons: current price action/technical trend is weak, and continued execution is needed into the next earnings cycle. Influential/politician activity: No recent congress trading data available; no politician trading signals provided.

5 Analyst Rating

Wall Street analysts forecast CEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CEVA is 36 USD with a low forecast of 33 USD and a high forecast of 40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 22.510

Low

Averages

High

Current: 22.510

Low

Averages

High

Barclays

Tavy Rosner

maintain

$30 -> $35

AI Analysis

2025-11-11

Reason

Barclays

Tavy Rosner

Price Target

$30 -> $35

AI Analysis

2025-11-11

maintain

Reason

Barclays analyst Tavy Rosner raised the firm's price target on Ceva to $35 from $30 and keeps an Overweight rating on the shares.

Roth Capital

Buy

upgrade

$30 -> $35

2025-11-10

Reason

Roth Capital

Price Target

$30 -> $35

2025-11-10

upgrade

Buy

Reason

Roth Capital raised the firm's price target on Ceva to $35 from $30 and keeps a Buy rating on the shares. The company's Q3 results topped estimates, and the firm is encouraged by broad end market royalty growth and robust licensing results, the analyst tells investors in a research note. The growing NeuPro AI IP licensing contribution bodes well for the secular growth opportunity, the firm added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CEVA

Unlock Now

CEVA Should I Buy

CEVA Should I Buy

Should You Buy CEVA Inc (CEVA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch